文献速递新发突发、热带与寄生虫病

化学预防对平民旅行者间日疟与原虫疟感染的影响:基于862例患者的嵌套病例对照研究与反事实方法

Impact of Chemoprophylaxis on Plasmodium vivax and Plasmodium ovale Infection Among Civilian Travelers: A Nested Case-Control Study With a Counterfactual Approach on 862 Patients.
PubMed 文献 · Clin Infect Dis · 2023-01-01

该嵌套病例对照研究分析了2006年1月1日至2017年12月31日法国输入性疟疾平民旅行者中间日疟和卵形疟感染结局,共247例间日疟和615例卵形疟感染者,其中分别有30%和47%使用了化学预防。使用化学预防者返回后超过2个月出现症状的风险更高(间日疟OR 2.91,95%CI 1.22-6.95,P=.02;卵形疟OR 2.28,95%CI 1.47-3.53,P<.001)。仅作用于红内期的药物与症状延迟至60天后出现相关,而阿托伐醌-氯胍则无此关联。

要点

  • 使用化学预防的间日疟和卵形疟旅行者返回后超过2个月出现症状的风险更高。
  • 间日疟OR 2.91(95%CI 1.22-6.95,P=.02),卵形疟OR 2.28(95%CI 1.47-3.53,P<.001)。
  • 仅作用于红内期的药物与症状延迟至60天后出现相关,阿托伐醌-氯胍无此关联。

核心结论

  • 使用化学预防(尤其是仅作用于红内期的药物)的间日疟或卵形疟感染平民旅行者,其症状延迟出现的风险更高。

研究设计与样本

  • 嵌套病例对照研究,纳入2006年1月1日至2017年12月31日法国输入性疟疾平民旅行者中间日疟和卵形疟感染病例,共247例间日疟和615例卵形疟患者。

主要发现

  • 247例间日疟和615例卵形疟感染者中,分别有30%和47%使用了化学预防,严重病例分别为7例(3%)和8例(1%)。
  • 使用化学预防者返回后超过2个月出现症状的风险更高:间日疟OR 2.91(95%CI 1.22-6.95,P=.02),卵形疟OR 2.28(95%CI 1.47-3.53,P<.001)。
  • 仅作用于红内期的药物与症状延迟至60天后出现相关,而使用阿托伐醌-氯胍则无此关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of chemoprophylaxis targeting Plasmodium falciparum on Plasmodium vivax and Plasmodium ovale, which may remain quiescent as hypnozoites in the liver, is debated. METHODS: We conducted a nested case-control analysis of the outcomes of P. vivax and P. ovale infections in imported malaria cases in France among civilian travelers from 1 January 2006, to 31 December 2017. Using adjusted logistic regression, we assessed the effect of chemoprophylaxis on the incubation period, time from symptoms to diagnosis, management, blood results, symptoms, and hospitalization duration. We analyzed the effect of blood-stage drugs (doxycycline, mefloquine, chloroquine, chloroquine-proguanil) or atovaquone-proguanil on the incubation period. We used a counterfactual approach to ascertain the causal effect of chemoprophylaxis on postinfection characteristics. RESULTS: Among 247 P. vivax- and 615 P. ovale-infected travelers, 30% and 47%, respectively, used chemoprophylaxis, and 7 (3%) and 8 (1%) were severe cases. Chemoprophylaxis users had a greater risk of presenting symptoms >2 months after returning for both species (P. vivax odds ratio [OR], 2.91 [95% confidence interval {CI}, 1.22-6.95], P = .02; P. ovale OR, 2.28 [95% CI, 1.47-3.53], P < .001). Using drugs only acting on the blood stage was associated with delayed symptom onset after 60 days, while using atovaquone-proguanil was not. CONCLUSIONS: Civilian travelers infected with P. vivax or P. ovale reporting chemoprophylaxis use, especially of blood-stage agents, had a greater risk of delayed onset of illness. The impact of chemoprophylaxis on the outcomes of infection with relapse-causing species calls for new chemoprophylaxis acting against erythrocytic and liver stages.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Le Goff M, Kendjo E, Thellier M, et al. Impact of Chemoprophylaxis on Plasmodium vivax and Plasmodium ovale Infection Among Civilian Travelers: A Nested Case-Control Study With a Counterfactual Approach on 862 Patients. Clin Infect Dis. 2023. PMID: 35962785. doi:10.1093/cid/ciac641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。